Entering text into the input field will update the search result below

Biohaven Pharma announces key milestones for 2018

May 15, 2018 4:35 PM ETBiohaven Ltd. (BHVN) StockBy: Douglas W. House, SA News Editor1 Comment
  • In its Q1 report, Biohaven Pharmaceutical (NYSE:BHVN) announces the following key future events for the year:
  • CGRP receptor antagonist platform:
  • Report initial results from a long-term safety study evaluating rimegepant in Q4 2018.
  • Report top-line results from a Phase 3 rimegepant Zydis ODT trial in Q4 2018.
  • Submit an IND and initiate a Phase 1 trial evaluating BHV-3500 for the acute treatment and prevention of migraine in 2018.
  • Submit an NDA for rimegepant to the FDA in 2019, having previously announced positive topline data from its first two pivotal Phase 3 trials.
  • Glutamate modulator platform:
  • Complete enrollment in a Phase 2 trial evaluating trigriluzole in OCD in 2018.
  • Report top-line results from a Phase 3 spinocerebellar ataxia long-term extension study in Q4 2018.
  • Initiate a Phase 2 clinical trial evaluating trigriluzole in Alzheimer's disease in collaboration with the Alzheimer's Disease Cooperative Study Group in Q2 2018.
  • Submit an NDA to the FDA via the 505(b)(2) pathway for BHV-0223 in patients with ALS in the second half of 2018.
  • Complete a Phase 1 trial for BHV-5000 in 2018.

Recommended For You

About BHVN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BHVN--
Biohaven Ltd.